PubMed Health⌕ Search

Biomedical subjects

V Engeler

Publications and source records attributed to V Engeler.

At least 19 recordsLinked to original sources
PubMed1996

Treatment of ovarian cancer with surgery, short-course chemotherapy and whole abdominal radiation.

BACKGROUND: The primary aim was to induce a high number of pCR in early (FIGO IC, IIB + C) - and advanced (FIGO III-IV) - stage ovarian cancer with a surgery plus 4 cycles of cisplatin and melphalan (PAMP) regimen. The second objective was to prevent relapse with WAR in patients in remission after chemotherapy. PATIENTS AND METHODS: 218 eligible patients were treated after staging laparotomy with cisplatin 80 mg/sqm i.v. on day 1 and melphalan 12 mg/sqm i.v. on day 2 q 4 weeks. Response was verified by second-look laparotomy. WAR was carried out with the open field technique on a linear accelerator (daily dose: 1.3 Gy, total dose: 29.9 Gy) in patients with pathological or clinical CR or pathological PR with microscopical residual disease. RESULTS: 146/218 patients (67%, 95% CI: 61%-73%) responded to PAMP: 56 (26%) achieved pCR, 24 (11%), cCR, 56 (26%) pPR and 10 (5%) cPR (c = clinical, p = pathological). Multivariate analyses revealed that in advanced stages (92 cases in remission), the achievement of pCR was the most important factor for longer time to failure (TTF) and survival. Only 51/118 (43%) patients in remission received WAR. Early-stage patients <= 55 years were more likely to have WAR than patients older than 55 years (77% vs. 23%; p = 0.02). Advanced-stage patients with cCR were less likely to be irradiated than patients with pCR or pPR (10% vs. 51%; p = 0.003). Toxicity of PAMP was acceptable with 10% of WHO grade 4 hematologic toxicity. Acute hematological toxicity of WAR caused interruption (33%) or incompleteness (33%) of irradiation in the majority of patients. CONCLUSIONS: PAMP is an effective treatment for advanced ovarian cancer with a 67% response rate after 4 cycles. For the majority of patients in remission, WAR as a consolidation treatment was hardly feasible. For these patients new treatment modalities to consolidate remission are needed.

Adult↗
PubMed1990

Adenocarcinoma of the uterine cervix. An analysis of 84 cases between 1970 and 1988.

Of 1284 cases with cervical carcinoma of Stages 0-IV treated at the Gynaecological University Hospital CH-Zurich between 1970 and 1988, 84 (6.5%) were adenocarcinomas; whereas a previous study performed at our clinic between 1950 and 1970 had only revealed an incidence of 3.2%. Compared with the 1200 cases of squamous cell carcinoma during the period from 1970 to 1988 it is of interest that patients with adenocarcinomas are slightly older (median value: 48 years, squamous cell carcinoma: 44 years) and that there is a temporary postmenopausal decrease in incidence: whereas there were 29 cases in the 45- to 54-year age group and 12 in the 65- to 74-age group, only 3 cases occurred in the 55- to 64-age group. Of the 38 women undergoing radical hysterectomy, 9 (24%) showed metastases in the pelvic lymph nodes. Of 115 squamous cell carcinomas operated in the same way, 15 (13%) were metastatic, which corresponds to a value of 3.65 (p = 0.057) in the chi-square test and is just below significance different. No metastases could be evidenced in any of the 28 adnexa removed bilaterally. The general appearance of the adenocarcinoma largely corresponds to that of its squamous cell counterpart of the cervix, although there are certain indications, confirmed by some references, as to poorer prognosis, earlier formation of lymph node metastases and slightly reduced radio-sensitivity.

Adenocarcinoma↗
PubMed1988

Treatment of advanced ovarian cancer with surgery, chemotherapy, and consolidation of response by whole-abdominal radiotherapy.

Between April 1981 and June 1985, 195 patients with ovarian cancer, International Federation of Gynecology and Obstetrics (FIGO) Stages IIB, IIC, III, and IV, entered a trial that consisted of surgery and chemotherapy with cisplatin (P) and melphalan (PAM) with or without hexamethylmelamine (HexaPAMP or PAMP regimens) every 4 weeks for 6 cycles. Because the intent was to study the outcome by treatment after evaluation of first-line chemotherapy, patients were evaluable only if the response was assessed by a second-look operation or if measurable disease progression was documented. One hundred fifty-eight patients (81%) were evaluable for response. Forty-five (28%) achieved pathologically confirmed complete remissions (pCR), and 24 of these patients received whole-abdominal radiation (WAR) for consolidation of response. Five patients with complete remission after WAR relapsed, as did nine of the 21 with complete remission who had not undergone WAR. The 3-year time to progression percentage (TTP +/- SE) from second-look operation was 70% +/- 7% for all patients who achieved pCR, 83% +/- 8% for those who received WAR, and 49% +/- 15% for those who did not receive WAR (this was not a randomized comparison). The 3-year TTP percentage for the 49 partial responders was 21% +/- 6%, identical for the 19 who had WAR and the 30 who had no radiation therapy. Additional or alternative methods for consolidation of pCR are needed since patients continue to relapse despite optimal initial response to therapy.

Abdomen↗
PubMed1982

[Bowenoid papulosis and Bowen's disease of the vulva].

The histological features of "bowenoid papulosis of the vulva" are practically identical to those found in Bowen's disease, and the differential diagnosis between these two lesions is based upon clinical data alone. The distinction between the two lesions is of importance as Bowen's disease represents a precancerous dermatosis and bowenoid papulosis a probably benign lesion of viral etiology. The clinical and histological features and therapy of the two vulvar diseases are analyzed and discussed in the light of 18 personally observed cases.

Adult↗
PubMed1981

[Primary carcinoma of the Fallopian tube--a clinical study of 37 cases (author's transl)].

Thirty-seven cases of primary fallopian tube carcinoma treated at our institution over the years 1946 to 1976 are described. The overall 5-years survival rate was 30%, although patients with early tumors had 42% survival rate. The single most important factor affecting survival appeared to be the extent of disease at the time of diagnosis. Present treatment modalities are discussed, even though the number of tube carcinomas are few, it might be useful to adopt an official classification.

Adult↗
PubMed1979

[The problem of the multifocal breast neoplasm].

Nowadays, it is accepted that mammary cancer does not represent a localized tumor only, but a bilateral disease of breast tissues. During a period of 6 years, bilateral manifestations of infiltrating cancer have been observed in 12.7% of all cases. 23.2% of all breast cancer patients had a unilaterial multicentric tumor. The implications of this phenomenon with regard to control and therapy are as follows: As early diagnosis of malignant breast tumors often is possible by means of mammography, this examination should be performed regulary in high-risk patients, especially in cases of known earlier malignancy of one breast. More radical surgery should have priority, in view of the frequently observed multicentricity of breast cancers.

Biopsy↗
PubMed1979

[The efficacy of chemotherapy in the treatment of cancer of the breast (author's transl)].

The article reports on two female patients with cancer of the breast who had primarily not been treated by surgery or exposure to radiation, but only with cytostatics. Complete remission of the tumour occurred in both patients in the course of several years of treatment. These two examples show that in patients with cancer of the breast in stages which appear refractory and hopeless, a treatment course with cytostatics should be attempted.

Antineoplastic Agents↗
PubMed1978

[The adenocarcinoma of the cervix: study of 81 cases (author's transl)].

The present study deals with 81 primary adenocarcinomas of the uterine cervix diagnosed and treated in the departement of gynecology and obstetrics of the University of Zürich from 1950 through 1977. Clinical and morphological data such as patients age, character and duration of symptoms, clinical and anatomical stage, histological differentiation of the tumor and therapy were recorded and analysed in relation to patients survival. Of all these factors the stage of the tumor at time of diagnosis proved to have the highest prognostic significance.

Adenocarcinoma↗